|
2014年3月，美國專利商標局(USPTO)發表了新的 「專利適格標的指南」 (Patent Eligibility Guidelines)，申明「天然產物」(natural products) 是不能夠被准予專利的，因此，專利審查委員如何依據新指南分析發明標的是否為「天然產物」，對生技類專利的審查結果將影響甚大。此外，綜觀近年來美國最高法院對於多件專利訴訟案所做出的決定，亦對生技及醫療相關產業帶來了各種重大影響。
飛翰外國法事務律師事務所將與您一同探討，在新的法令規範下，生技產業如何以精準策略提升專利申請案的核准率；市場開發與專利權的運用息息相關，又該如何規劃專利布局以廣開獲利途徑。
主辦單位：中華民國生物產業發展協會、飛翰外國法事務律師事務所
時 間：2014年7月25日
地 點：世貿南港展覽館5樓504A室
語 言：英文
聯 絡 人：陳毓玲 02-2712-7001 #113 [email protected]
報名方式：網路報名 www.bio-taiwan.com/apply/bio_form-02.php
選擇包含"主題研討會及座談會"之方案
議程
| Time |
Topics |
Speakers |
| 09:30 – 10:00 |
Registration |
|
| 10:00 – 10:10 |
Opening Remarks |
Gary C. Ma
Resident Managing Partner
Finnegan, Henderson, Farabow, Garrett, & Dunner, LLP. |
| 10:20 – 11:10 |
Update on Recent U.S. Supreme Court Patent Cases |
Susan Griffen
Partner
Finnegan, Henderson, Farabow, Garrett, & Dunner, LLP. |
| An overview of recent U.S. Supreme Court patent cases and how they can affect biotech companies, including a discussion of cases involving patent definiteness, joint infringement, and patentable subject matter.。 |
| 11:10 – 12:00 |
Understanding the New Subject Matter Eligibility Guidelines and Its Effects on Biotech Inventions. |
William L. Strauss Ph.D.
Partner
Finnegan, Henderson, Farabow, Garrett, & Dunner, LLP. |
| In March 2014, the U.S. Patent and Trademark Office issued new guidelines for subject matter eligibility in view of recent U.S. Supreme Court decisions. The Guidelines will directly impact how patent examiners will analyze any claims reciting “natural products.” We will discuss the three-question flowchart, twelve itemized questions for analyzing subject matter eligibility, and the eight examples provided in the Guidelines. We will offer strategic considerations for avoiding a § 101 rejection for biotech inventions. |
*大會保留議程因人為及不可抗因素之變更權利。
|
